Table 1.

COVID-19 vaccines as emergency use issued by the WHO.

Candidate vaccine	Vaccine platform description	Developer	Number of doses	Schedule	Route of administration	Storage temperature	Number of approved countries	Potential serious side effects
mRNA-1273 (Spikevax)	mRNA	Moderna	2	Day 0 + 28	Intramuscular	2–8°C for 30 days, −20°C for 6 months	88	Myocarditis and pericarditis
BNT162b2 (Comirnaty)	mRNA	Pfizer/BioNTech	2	Day 0 + 21	Intramuscular	−70°C	148	–
COVOVAX (Novavax formulation)	Protein subunit	Serum Institute of India	2	Day 0 + 21	Intramuscular	2–8°C	5	–
Nuvaxovid	Protein subunit	Novavax	2	Day 0 + 21	Intramuscular	2–8°C	39	–
Ad5-nCov (Convidecia)	Replication-defective adenovirus type 5 vector	CanSino	2	Day 0 + 21	Intramuscular	2–8°C	10	Thrombotic thrombocytopenia syndrome
Ad26.COV2.S	Replication-incompetent human adenovirus type 26 vector	Janssen (Johnson & Johnson)	1–2	Day 0 or Day 0 + 56	Intramuscular	2–8°C	113	Thrombotic thrombocytopenia syndrome and Guillain-Barré syndrome
AZD1222 (Vaxzevria)	Replication-defective chimpanzee adenovirus vector	Oxford/AstraZeneca	1–2	Day 0 or Day 0 + 28	Intramuscular	2–8°C	148	Thrombotic thrombocytopenia syndrome and Guillain-Barré syndrome
Covishield	Replication-defective chimpanzee adenovirus vector	Serum Institute of India	1–2	Day 0 or Day 0 + 28	Intramuscular	2–8°C	49	Thrombotic thrombocytopenia syndrome and Guillain-Barré syndrome
Covaxin	Inactivated	Bharat Biotech	2	Day 0 + 14	Intramuscular	2–8°C	14	–
BBIBP-CorV (Covilo)	Inactivated	Sinopharm (Beijing)	2	Day 0 + 21	Intramuscular	2–8°C	93	–
CoronaVac	Inactivated	Sinovac	2	Day 0 + 14	Intramuscular	2–8°C	56	–

COVID-19: Coronavirus disease 2019; mRNA: Messenger ribonucleic acid; WHO: World Health Organization. https://covid19.trackvaccines.org/agency/who/.